The lesson here is not just that a regulation changed — it's that manufacturers who wait for enforcement pressure to update their regulatory strategy will pay a steep price in time, money, and market access. FDA's reclassification of optical diagnostic devices for melanoma detection is a textbook example of how proactive compliance positioning separates market leaders from laggards.
On March 25, 2026, the U.S. Food and Drug Administration published a final order in the Federal Register (Docket No. FDA-2020-N-2002) formally reclassifying two postamendments Class III device types into Class II (Special Controls), subject to premarket notification (510(k)):
- Product Code OYD – Optical diagnostic devices for melanoma detection
- Product Code ONV – Electrical impedance spectrometers
Both device types are also being renamed and codified under a new classification regulation: "software-aided adjunctive diagnostic devices for use on skin lesions by physicians." This is not a minor administrative update. It fundamentally reshapes the regulatory pathway, market entry requirements, and ongoing compliance obligations for a growing category of AI- and software-driven dermatology tools.
If your organization manufactures, distributes, or is developing devices in either of these product codes, read carefully. The window to act is open — but it won't stay that way.
What Changed: Breaking Down the FDA's Final Order
From Class III to Class II — Why It Matters
Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), medical devices are stratified into three regulatory classes based on risk:
| Class | Risk Level | Primary Control Pathway | Examples |
|---|---|---|---|
| Class I | Low | General Controls | Bandages, tongue depressors |
| Class II | Moderate | General Controls + Special Controls + 510(k) | Software-aided diagnostic tools (post-reclassification) |
| Class III | High | Premarket Approval (PMA) | Implantable pacemakers, novel high-risk devices |
Prior to this final order, optical melanoma detection devices (OYD) and electrical impedance spectrometers (ONV) were classified as Class III — meaning any manufacturer seeking to market such a device needed to submit a full Premarket Approval (PMA) application, a process that typically takes 180 days at minimum, costs hundreds of thousands of dollars, and carries significant clinical data burdens.
After this final order, these devices are reclassified to Class II, meaning the primary pathway to market becomes the 510(k) premarket notification, combined with adherence to FDA-defined Special Controls specific to this new device category.
This is a meaningful regulatory easing — but it comes with a new set of compliance requirements that manufacturers must understand precisely.
The New Device Name and Regulation
FDA is codifying these devices under a new regulatory identity: "software-aided adjunctive diagnostic devices for use on skin lesions by physicians." This rename is significant for several reasons:
- It signals FDA's recognition that this device category is now predominantly software-driven, including AI/ML-based decision support tools.
- The term "adjunctive" is deliberate — these devices are cleared to support, not replace, physician clinical judgment. This framing directly informs intended use language, labeling requirements, and permissible promotional claims.
- The "by physicians" qualifier signals that use by non-physician practitioners may require separate regulatory consideration.
Manufacturers must ensure their 510(k) submissions, labeling, instructions for use (IFU), and marketing materials are fully harmonized with this new classification language.
The Special Controls: Your New Compliance Framework
Reclassification to Class II doesn't mean fewer requirements — it means different and more tailored requirements. Special Controls for this device category are designed to address residual risks that general controls alone cannot mitigate. Based on FDA's reclassification order and the agency's precedent in adjacent AI/software-driven device categories, manufacturers should expect Special Controls to include provisions addressing:
1. Performance Testing Requirements
Devices in this category must demonstrate clinical performance through sensitivity, specificity, and positive/negative predictive value (PPV/NPV) data for melanoma detection relative to established clinical benchmarks. FDA has historically required this data to be stratified by skin tone, lesion type, and clinical setting.
2. Labeling and Intended Use Controls
- Clear "adjunctive use only" statements
- Prominent physician-direction disclosures
- Limitations of use sections addressing populations where performance data is limited (e.g., darker Fitzpatrick skin phototypes)
- Software version disclosure and update notification obligations
3. Software Documentation (for SaMD-enabled devices)
Devices incorporating Software as a Medical Device (SaMD) — including AI/ML algorithms — must comply with FDA's Software as a Medical Device guidance and, increasingly, align with the International Medical Device Regulators Forum (IMDRF) SaMD framework. This means:
- Software Bill of Materials (SBOM)
- Algorithm training data documentation
- Performance validation across diverse datasets
- Change control protocols that address when algorithm updates trigger new 510(k) submissions
4. Postmarket Surveillance
Expect requirements for Medical Device Reporting (MDR) under 21 CFR Part 803, potentially including enhanced vigilance protocols for missed melanoma diagnoses (false negatives), given the life-threatening consequences of delayed detection.
Effective Dates and Compliance Deadlines
This is where urgency becomes real. FDA's final order establishing the reclassification is effective upon publication on March 25, 2026. However, the practical compliance timeline breaks down as follows:
| Milestone | Date / Timeline | Action Required |
|---|---|---|
| Final Order Published | March 25, 2026 | Note new device classification, begin regulatory gap assessment |
| Reclassification Effective | March 25, 2026 | OYD and ONV devices are now officially Class II |
| 510(k) Pathway Opens | Immediately | New market entrants may now submit 510(k) vs. PMA |
| Existing PMA Holders | Per FDA transition guidance | Monitor FDA for specific transition provisions |
| Special Controls Compliance | Per 510(k) clearance cycle | All new submissions must address Special Controls |
| Labeling Updates | At next product revision cycle / immediately for new devices | All labeling must reflect new device name and adjunctive use framing |
Citation Hook: FDA's March 25, 2026 final order reclassifying optical melanoma detection devices (product code OYD) and electrical impedance spectrometers (product code ONV) from Class III to Class II (Special Controls) represents the most significant regulatory pathway change for skin lesion diagnostic technology in over a decade.
For manufacturers currently marketing devices under a PMA: FDA's reclassification does not automatically void your PMA. However, you now have the option to transition to a 510(k) framework. Watch for FDA guidance on the PMA-to-510(k) transition process. Some manufacturers may find it strategically advantageous to retain their PMA status, particularly if they have substantial sunk costs in clinical data that differentiates them competitively.
For manufacturers with devices in development: The 510(k) pathway is now available immediately. Do not submit a PMA for a device in product codes OYD or ONV without first consulting with a regulatory expert — you would be pursuing an unnecessary and expensive pathway.
Why This Reclassification Happened: The Regulatory Context
FDA does not reclassify devices arbitrarily. Understanding the rationale behind this order helps manufacturers anticipate what compliance will look like in practice.
The Role of the De Novo Process and Predicate Establishment
Reclassification to Class II requires FDA to find that general controls and special controls are sufficient to provide reasonable assurance of safety and effectiveness — a lower risk threshold than Class III, where only PMA-level evidence suffices. This determination reflects:
- Accumulating real-world evidence that software-aided melanoma detection tools, when used adjunctively by trained physicians, present a manageable risk profile.
- The establishment of a Special Controls framework rigorous enough to address residual risks, including false negatives, algorithm bias, and inappropriate non-physician use.
- Industry maturation — the melanoma diagnostic device market has grown substantially, with multiple devices having undergone rigorous FDA review, providing a body of safety and effectiveness data sufficient to anchor a 510(k) predicate ecosystem.
According to the American Cancer Society, melanoma accounts for only about 1% of skin cancers but causes the large majority of skin cancer deaths. The global AI-powered dermatology diagnostics market is projected to exceed $3.4 billion by 2030, with optical and software-aided detection tools representing a rapidly expanding share. FDA's reclassification reflects both the clinical need and the technological maturity of this device class.
Citation Hook: The FDA's reclassification of melanoma detection devices under 21 CFR (General and Plastic Surgery Devices) into Class II with Special Controls establishes a new predicate ecosystem, meaning any manufacturer with a cleared 510(k) in product codes OYD or ONV can serve as a valid predicate device for subsequent 510(k) submissions — dramatically lowering the barrier to innovation in this space.
Practical Compliance Guidance: What Manufacturers Should Do Right Now
At Certify Consulting, I've guided more than 200 medical device clients through regulatory transitions — from de novo petitions to PMA supplements to 510(k) submissions — and I can tell you that the manufacturers who fare best in moments like this are the ones who treat a regulatory change as a strategic opportunity, not just a compliance checkbox.
Here's the practical roadmap:
Step 1: Conduct a Regulatory Classification Audit (Do This Week)
Review every device in your portfolio and pipeline against product codes OYD and ONV. Determine: - Is your device currently classified under these codes? - Are you in development with an intended OYD/ONV classification? - Does your device's intended use fall within "software-aided adjunctive diagnostic devices for use on skin lesions by physicians"?
If the answer to any of these is "yes" or "maybe," you need a formal regulatory gap assessment before your next product or strategy meeting.
Step 2: Update Your Regulatory Strategy Documents
Your Regulatory Strategy Memo, 510(k) Pre-Submission (Q-Sub) strategy, and Design History File (DHF) should all be updated to reflect: - The new device classification name and code - The Special Controls framework - Intended use language consistent with "adjunctive" diagnostic support
Step 3: Review and Revise Your Labeling
This is non-negotiable. Labeling that does not reflect the new device name and intended use framing is misbranded under 21 CFR 801. At minimum: - Update the device name in all labeling components - Ensure "adjunctive use by physicians only" language is prominently included - Revise your IFU to address any new Special Controls-driven disclosure requirements
Step 4: Assess Your SaMD Compliance Posture
If your device incorporates AI/ML algorithms (as most devices in this category increasingly do), ensure you have documented: - Algorithm training and validation datasets - Predetermined change control protocols (per FDA's 2021 AI/ML Action Plan) - Bias assessment across Fitzpatrick phototype scales I–VI - Version control and change documentation
Step 5: Engage FDA Early via the Q-Sub Program
If you're preparing a 510(k) submission for a device in this reclassified category, I strongly recommend submitting a Pre-Submission (Q-Sub) to FDA before your 510(k) filing. The Q-Sub process allows you to align with FDA on: - Appropriate performance testing protocol and acceptance criteria - Predicate device selection strategy - Special Controls compliance approach
In my experience, manufacturers who engage FDA early through Q-Subs reduce 510(k) review cycles by an average of 30–60 days and dramatically reduce the risk of Additional Information (AI) requests that can stall clearance for months.
Citation Hook: Under the newly established Class II framework for software-aided adjunctive melanoma diagnostic devices, manufacturers who fail to align their 510(k) submissions with the applicable Special Controls — particularly around software documentation and clinical performance data — risk receiving a Not Substantially Equivalent (NSE) determination, effectively blocking market entry.
Competitive Implications: Who Benefits, Who Is at Risk
Winners Under the New Framework
- Established SaMD companies with existing AI/ML pipelines who can rapidly adapt their technology to meet Special Controls without the PMA burden
- Mid-market device manufacturers who previously could not absorb PMA costs but can now pursue 510(k) clearance
- Academic medical centers and spinouts developing novel optical or impedance-based skin lesion tools who now have a viable commercial pathway
Companies at Risk
- Incumbents with PMA-cleared devices who do not proactively evaluate the PMA-to-510(k) transition — competitors with lower entry costs will erode their market position
- Manufacturers with non-compliant labeling who fail to update intended use language — misbranding exposure is real and immediate
- AI/ML device developers who have not documented algorithm training data or bias assessments — Special Controls will require this, and FDA's review teams are increasingly sophisticated in SaMD review
How Certify Consulting Can Help
At Certify Consulting, we specialize in navigating exactly these kinds of regulatory transitions. With over 200 clients served and a 100% first-time audit pass rate, our team has the depth of experience to move quickly and accurately when timelines are compressed.
Our services for manufacturers impacted by this reclassification include:
- Regulatory classification audits for OYD/ONV portfolio and pipeline devices
- 510(k) preparation and submission management, including Special Controls documentation
- FDA Q-Sub strategy and preparation for pre-submission alignment
- SaMD compliance assessments aligned with FDA's AI/ML Action Plan and IMDRF frameworks
- Labeling review and revision for compliance with new classification language
- PMA-to-510(k) transition planning for existing PMA holders
Learn more about our medical device regulatory consulting services at certify.consulting or explore our 510(k) submission support resources to understand how we can accelerate your path to clearance.
Frequently Asked Questions
Does this reclassification mean my existing cleared device needs a new 510(k)?
Not automatically. If your device is already cleared under product code OYD or ONV, you are not required to submit a new 510(k) solely because of the reclassification. However, you must ensure your labeling and ongoing compliance obligations align with the new Special Controls. Significant changes to your device — including software algorithm updates — may independently trigger a new 510(k).
Can non-physicians use these devices after reclassification?
The new classification name specifies "use on skin lesions by physicians," which signals FDA's intent that these devices are cleared for physician use. Non-physician use — including by nurse practitioners, physician assistants, or consumers — is not covered by the cleared intended use and would constitute off-label use with potential regulatory and liability consequences.
What is the difference between a PMA and a 510(k) for these devices?
A PMA (Premarket Approval) is the most rigorous FDA review pathway, required for Class III devices, and demands extensive clinical trial data and a lengthy, expensive review process. A 510(k) (Premarket Notification) requires manufacturers to demonstrate that their device is substantially equivalent to a legally marketed predicate device. The reclassification to Class II means the 510(k) pathway — significantly faster and less costly — is now the primary route to market for OYD and ONV devices.
When do the Special Controls for these reclassified devices take effect?
The reclassification and its associated Special Controls are effective as of the final order publication date, March 25, 2026. All new 510(k) submissions for devices in product codes OYD and ONV must address the Special Controls from this date forward.
What if my device uses AI/ML — are there additional requirements?
Yes. Software-aided devices that incorporate AI or machine learning algorithms are subject to FDA's evolving SaMD guidance framework, including the 2021 AI/ML-Based Software as a Medical Device Action Plan. Manufacturers must document algorithm training and validation data, implement predetermined change control protocols, and conduct bias assessments across diverse patient populations, including Fitzpatrick skin phototype diversity. These requirements will be reflected in the applicable Special Controls for this device category.
Last updated: 2026-04-08
Jared Clark is the Principal Consultant at Certify Consulting, holding credentials including JD, MBA, PMP, CMQ-OE, CPGP, CFSQA, and RAC. With over 8 years of experience and more than 200 clients served, Certify Consulting delivers full-service regulatory and certification consulting for medical device manufacturers, life sciences companies, and healthcare organizations. Visit certify.consulting to learn more.
Source: U.S. Food and Drug Administration, Federal Register, Vol. 91, March 25, 2026. "General and Plastic Surgery Devices; Reclassification of Optical Diagnostic Devices for Melanoma Detection." Docket No. FDA-2020-N-2002.
Jared Clark
Principal Consultant, Certify Consulting
Jared Clark is the founder of Certify Consulting, helping organizations achieve and maintain compliance with international standards and regulatory requirements.